Rhythm Pharmaceuticals, based in Boston, develops therapeutics for rare diseases, focusing on melanocortin-4 receptor agonists like IMCIVREE, approved for chronic weight management in specific obesity cases. The company employs 226 people and went public in October 2017.
Yann Mazabraud sold 17,750 shares of RYTM on 8 April at $61.54 per share, worth a total of $1.1M. They now own 31,932 RYTM shares, or a 44% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
